Synchron, which is developing a brain-computer interface that helps paralysis patients text, email, and shop online, raises $40M Series B led by Khosla Ventures
Context & Ripple Effects
In 2021 this was an early bet on an unusual delivery mechanism: Synchron's implant threads into the brain through blood vessels rather than open surgery, which is what made the vessel-inserted implant trial profile plausible as a scalable product for paralysis patients who need to text, email, and shop. The $40M Khosla-led Series B was the round that funded that thesis before anyone knew if it would hold.
It did, at least on the funding curve: Khosla's lead positioned it ahead of the $75M round backed by Bezos Expeditions and Gates Frontier two years later, the Apple partnership on iPhone control via the stent-like implant in 2025, and the $200M Series D at a nearly $1B valuation. This article is the first data point in that escalation.
First-order effects
- Synchron gets capital to advance clinical development of its circulatory-system implant for texting, emailing, and shopping use cases — work that later produced hands-free Alexa and iPhone control for users with paralysis.
Second-order effects
- The round validated the less-invasive approach enough to pull in marquee follow-on money (ARCH Venture, Bezos Expeditions, Gates Frontier) and eventually Apple as a device-side partner, shifting competition toward whoever pairs implants with consumer ecosystems.
Third-order effects
- If vessel-delivered implants keep clearing funding and partnership milestones, brain-computer interfaces split into invasive-surgery versus minimally invasive camps — with even hardware-light entries like Sabi's speech-decoding beanie, also Khosla-backed, competing on the same accessibility promise.
The trend: Brain-computer interfaces are moving from research-stage implants toward consumer-device integrations, with early venture leads like Khosla Ventures compounding their positions across successive rounds.